JD HEALTH(06618) 国信证券·2025-03-08 13:31Investment Rating - The investment rating for JD Health (06618.HK) is "Outperform the Market" [1][3][12] Core Views - In H2 2024, JD Health achieved a revenue of 29.8 billion yuan, representing a year-on-year increase of 13%. The growth was driven by an increase in active user numbers and a wider range of product categories [1][8] - The company's non-IFRS net profit margin improved from 6.4% in the previous year to 7.2%, with operating profit margin rising from -1% to 2%, primarily due to improvements in gross margin and administrative expense ratios [2][8] - For 2025, the management plans to increase long-term strategic investments to capitalize on structural changes in the healthcare market, expecting significant revenue and profit improvements over the next three years [2][8] Revenue and Profit Forecast - Revenue forecasts for 2025 and 2026 are set at 65.7 billion yuan and 73.5 billion yuan, respectively, with adjustments of 2.9% and 3.7% upwards due to increased consumer online purchasing behavior [3][12] - Adjusted net profit for 2025 and 2026 is projected at 4.4 billion yuan and 4.9 billion yuan, with downward adjustments of 7.9% and 3.2% due to increased investments in front warehouses and AI [3][12] Operational Data - As of H2 2024, JD Health had 184 million annual active users, a 7% year-on-year increase, indicating a user penetration rate of 27% with significant growth potential [2][9] - The average transaction value decreased year-on-year, but this was offset by an increase in shopping frequency among users [9]